28
Views
3
CrossRef citations to date
0
Altmetric
Original Article

Prostate Cancer Presenting with Normal Serum PSA Levels and Boney Metastases Treated with Zoledronic Acid

(Professor of Radiology and Director of Radiology) (Assistant Professor) (Professor of Radiology and Director of Radiology) (Assistant Professor) , , &
Pages 41-45 | Received 02 Oct 2004, Accepted 10 Jan 2005, Published online: 17 Aug 2009

References

  • Jacobs S C. Spread of prostate cancer to bone. Urology 1983; 21: 337–44
  • Kwak C, Seong J, Park M S, et al. Prognostic Significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002; 168: 995–1000
  • Lee C T, Oesterling J E. Using prostate-spe-cific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 1997; 24: 389–94
  • Oken M M, Creech R H, Tormey D C, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–55
  • Demetri G D, Kris M, Wade J, et al. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998; 16: 3412–25
  • Gough I R, Furnival C M, Schilder L, et al. Assessment of the quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol 1983; 19: 1161–65
  • McCormack H M, Horne D J, Sheather S, et al. Clinical applications of visual analog scales: A critical review. Psychol Med 1988; 18: 1007–19
  • Wymenga L FA, Boomsma J HB, Groenier K, et al. Routine bone scans in patients with prostate cancer related to serum prostate specific antigen and alkaline phosphatase. BJU Int 2001; 88: 226–30
  • Saad F. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Semin Oncol 2002; 29(Suppl 21)19–27
  • Smith M R, Eastham J, Gleason D M, et al. Randomised controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008–12
  • Lee M V, Fong E M, Singer F R, et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602–8
  • Terogen O, Heikkila P, Kontinen Y T, et al. MMP inhibition and down regulation by bisphosphonates. Ann NY Acad Sci 1999; 878: 453–65
  • Keller E T. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today 2002; 38: 91–102
  • Garnero P. Markers of bone turnover in prostate ancer. Cancer Treat Rev 2001; 27: 187–92

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.